This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Substance P increased pyroptotic cell death and inflammation in bronchial cells, activating the PI3K/AKT/NF-κB pathway.
Why it matters
Understanding how Substance P exacerbates asthma could lead to new therapeutic approaches to manage the condition. Targeting the pathways involved may help reduce inflammation and improve patient outcomes.
How the study worked
The study used clinical data from asthma patients and pre-clinical experiments with bronchial epithelial cells and asthmatic mice models to analyze the effects of Substance P.
What this study cannot tell us
The study primarily focuses on in vitro and animal models, which may not fully represent human asthma pathology.
Read the original research
Substance P promotes the progression of bronchial asthma through activating the PI3K/AKT/NF-κB pathway mediated cellular inflammation and pyroptotic cell death in bronchial epithelial cells.
Cell cycle (Georgetown, Tex.), 21(20), 2179-2191
Citation
Li, Miao; Zhong, Xiao; Xu, Wen-Ting. (2022). Substance P promotes the progression of bronchial asthma through activating the PI3K/AKT/NF-κB pathway mediated cellular inflammation and pyroptotic cell death in bronchial epithelial cells.. Cell cycle (Georgetown, Tex.), 21(20), 2179-2191. https://doi.org/10.1080/15384101.2022.2092166